Light Microscopic Study on Possible Protective Effect of Vitamin E on Imatinib IHCV Dilatation in Albino Rats

Abstract

Aim: To observe the changes in the caliber of hepatic central vein of Albino rats exposed to the oral administration of toxic doses of Imatinib and to assess the protective effect of vitamin E. Study design: Experimental study Place and duration of study: Department of Pharmacy, Peshawar Medical College Peshawar from 1st October 2015 to 31st March 2016. Methodology: Twenty four male Sprague-Dawley rats (150- 200g) were selected for this study and these rats were divided into three groups. Group 1 was control group, Group II received oral Imatinib solution (50 mg/kg/day) and Group III received Imatinib solution (50mg/kg/day) orally along with vitamin- E (500MG/kg/day) for 14 days. At the end of experiment central vein dilatation in liver tissue of rats were observed. Results: The increase in mean central vein dilatation in liver of group II were statistically significant (p=0.001) in comparison with the control. The mean central vein caliber of liver was decreased significantly in group III. Conclusion: The simultaneous use of vitamin E as an antioxidant with Imatinib can protect the toxic effects of the Imatinib on hepatic toxicity which includes central vein dilatation. Keywords: Imatinib mesylate, Hepatic tissue, Central vein dilatation, Vitamin E